Oncology

November 19th 2024

Outpatient models are emerging as feasible alternatives to traditional inpatient care, offering potential benefits such as reduced hospitalization, improved social well-being, and cost savings.

November 18th 2024

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

November 18th 2024

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

November 15th 2024

The indication is for adult and pediatric patients 1 year and older with a lysine methyltransferase 2A gene translocation.